Hatch-Waxman & Biologics Chair Chad Landmon discusses how the U.S. Supreme Court appears inclined to issue a narrow ruling in the Hikma v. Amarin “skinny label” case, with several justices signaling that existing inducement law may be sufficient rather than creating a new standard. He notes that the Court’s focus suggests a preference for resolving the dispute on its specific facts, rather than broadly redefining how generic drug makers can avoid patent infringement liability. Landmon highlights that while a limited decision may preserve flexibility, it leaves continued uncertainty for pharmaceutical companies navigating the risks associated with skinny labeling.